Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
Conference Call & Webcast Detail:
Date: Thursday, August 14, 2025
Time: 8:30 a.m. Eastern Time
Webcast Link: https://edge.media-server.com/mmc/p/de4jxxzj
Participant Link: https://register-conf.media-server.com/register/BI3e750b95d06c439ea560b46f60abda54
To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to sparing cancer patients further hardship by protecting their ears against the profound threat of cisplatin-induced hearing loss, or ototoxicity. Fennec is focused on the commercialization of PEDMARK ® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI.
In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI ® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in the U.K. and Germany.
PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.
For more information, please visit www.fennecpharma.com and follow on LinkedIn.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Lam Research Corp: Navigating the Financial Risks of Global Health Crises
Lam Research Corp (LRCX) has disclosed a new risk, in the Natural and Human Disruptions category. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Lam Research Corp faces significant risks from epidemics, pandemics, or disease outbreaks, which can severely impact its business operations and financial performance. Governmental measures to control disease spread, such as quarantines and travel bans, can restrict business activities, leading to facility closures, production delays, and supply chain disruptions. These challenges may result in increased costs, reduced revenues, and decreased profitability, potentially causing material adverse effects on the company's financial results. Additionally, global health crises can disrupt financial markets and economic stability, affecting customer demand and the company's access to financing. The average LRCX stock price target is $112.52, implying 6.88% upside potential. To learn more about Lam Research Corp's risk factors, click here.
Globe and Mail
an hour ago
- Globe and Mail
Stock Market Today: Bitmine Pops 5% as Crypto Infrastructure Stocks Surge
Bitmine Immersion Technologies (NYSEMKT: BMNR) rallied 5.9% on Wednesday to close at $62.44, extending its recent gains on a sharp uptick in trading volume. More than 128 million shares changed hands--nearly five times the company's three-month average--suggesting growing interest in the crypto infrastructure space. The stock remains well off its 52-week high of $161.00 but has recovered dramatically from its low of $1.93 earlier this year. Markets broadly advanced, with the Nasdaq Composite gaining 1.4% and the S&P 500 rising 1.1%, lifted by encouraging inflation data and renewed risk appetite across tech and growth sectors. Bitmine outperformed other crypto-exposed names, with Riot Platforms (NASDAQ: RIOT) rising 2.8% and Marathon Digital Holdings Inc (NASDAQ: MARA) up just 0.4%. Traders appear to favor Bitmine's differentiated positioning in immersion cooling infrastructure -- a technology increasingly adopted by large-scale Bitcoin (CRYPTO: BTC) miners and artificial intelligence (AI) server operators. Investor interest followed Bitmine's announcement that it plans to issue up to $20 billion worth of new stock to purchase additional Ethereum (CRYPTO: ETH) for its corporate treasury. The move, which would represent one of the largest public crypto accumulation strategies to date, reflects the company's aggressive bet on Ethereum's long-term value and potential to serve as a foundational asset for its infrastructure and liquidity goals. Should you invest $1,000 in Bitmine Immersion Technologies right now? Before you buy stock in Bitmine Immersion Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bitmine Immersion Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Daily Stock News has no position in any of the stocks mentioned. This article was generated with GPT-4o, OpenAI's large-scale language-generation model and has been reviewed by The Motley Fool's AI quality control systems.
Toronto Star
an hour ago
- Toronto Star
Cornish Metals Releases Unaudited Financial Statements and Management's Discussion and Analysis for the Six Months Ended 30 June 2025
VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) — Cornish Metals Inc. (TSX-V/AIM: CUSN) ('Cornish Metals' or the 'Company'), a mineral exploration and development company focused on advancing its wholly owned and permitted South Crofty tin project in Cornwall, United Kingdom, is pleased to announce that it has released its unaudited financial statements and management, discussion and analysis ('MD&A') for the six months ended June 30, 2025. The reports are available under the Company's profile on SEDAR+ ( and on the Company's website (
